We are advancing novel science and accelerating potential breakthrough therapies with the goal of delivering transformative medicines and vaccines, and possibly even cures, to patients in need. We focus our efforts in areas where we believe we are best positioned to utilize our expertise and bring unique, needed therapies to patients. More and more, our scientists are reaching into a dynamic R&D ecosystem to find the right partners to improve and accelerate our efforts. This focus and effort are helping to drive our long-term growth.
* Includes Hospira patents. Does not include licensed-in patents.
We're investigating precision-guided therapies targeting novel signaling and epigenetic pathways, and cancer immunotherapies aimed at modulating the immune system.
We are tackling some of the most deadly pediatric, adult and adolescent infectious diseases, as well as evaluating therapeutic vaccines across a variety of cancer types.
We are exploring Parkinson's, Alzheimer's and Huntington's disease, as well as conducting research into trans-diagnostic domains, where we explore how cognition, anxiety and motivation correlate to the manifestation of a neuropsychiatric disorder, and their impact on a patient's quality of life.
Our clinical-stage pipeline of potential therapies for patients covers a range of metabolic and cardiovascular risk factors, as well as exploring the areas of heart failure and nonalcoholic liver inflammation and damage.
We are looking to transform the treatment of chronic inflammatory diseases such as rheumatoid arthritis and gastrointestinal disorders, while investigating potential therapies with application in medical dermatology.
Our researchers in rare disease are working to unlock the scientific opportunity of gene therapy for people living with hemophilia, as well as investigating potential therapies for blood and neuromuscular diseases, which are devastating to patients, their families and the larger community.
With our acquisition of Hospira, we are now a leading global biosimilars company with a robust pipeline, best-in-class development capabilities and extensive real-world commercialization experience. We are working hard to extend that leadership by advancing high quality biosimilars to address the evolving needs of patients, payers and health systems.
Our strategy looks to foster collaboration across the biomedical ecosystem to deliver innovation to patients. We are working to bring the best science, wherever it resides, into our efforts to find and develop needed therapies.
We attempt to establish flexible collaborations that can have an amplifying and accelerating effect — optimizing shared assets and capabilities and making it possible to pursue more research avenues or de-risking the earlier stage research that may provide the foundation for true medical breakthroughs. In these new forms of collaboration, we are sharing in the risks and rewards and attempting to expedite the pace of innovation and enhance the R&D ecosystem for the benefit of patients.
